Cargando…

Prevalence of APOL1 Risk Variants in Afro-Descendant Patients with Chronic Kidney Disease in a Latin American Country

INTRODUCTION: In Colombia, the genetic background of the populations was shaped by different levels of admixture between Natives, European, and Africans. Approximately 35.363 patients have diagnosed chronic kidney disease and according to population studies, 10.4% of these patients are Afro-descenda...

Descripción completa

Detalles Bibliográficos
Autores principales: Duran, Carlos E., Ramírez, Alejandro, Posada, Juan G., Schweineberg, Johanna, Mesa, Liliana, Pachajoa, Harry, Estacio, Mayra, Manzi, Eliana, Aros, Vanessa, Díaz, Lorena, Garcia, Victor H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6935820/
https://www.ncbi.nlm.nih.gov/pubmed/31929905
http://dx.doi.org/10.1155/2019/7076326
_version_ 1783483639847190528
author Duran, Carlos E.
Ramírez, Alejandro
Posada, Juan G.
Schweineberg, Johanna
Mesa, Liliana
Pachajoa, Harry
Estacio, Mayra
Manzi, Eliana
Aros, Vanessa
Díaz, Lorena
Garcia, Victor H.
author_facet Duran, Carlos E.
Ramírez, Alejandro
Posada, Juan G.
Schweineberg, Johanna
Mesa, Liliana
Pachajoa, Harry
Estacio, Mayra
Manzi, Eliana
Aros, Vanessa
Díaz, Lorena
Garcia, Victor H.
author_sort Duran, Carlos E.
collection PubMed
description INTRODUCTION: In Colombia, the genetic background of the populations was shaped by different levels of admixture between Natives, European, and Africans. Approximately 35.363 patients have diagnosed chronic kidney disease and according to population studies, 10.4% of these patients are Afro-descendant. We aim to assess the frequency of APOL1 variants G1 and G2 in Afro-descendant patients with ESRD treated at la Fundacion Valle del Lili University Hospital in Cali, Colombia. METHODS: This is an observational cross-sectional study. Afro-descendant patients with ESRD in waitlist or recipients of kidney transplant were evaluated. Clinical data were collected from the electronic medical records. Genotyping was carried out by amplification of the exon 7 of the APOL1 gene. For the identification of risk genotypes, the bioinformatics tool BLAST was used. RESULTS: We enrolled 102 participants. The frequency of APOL1 risk variants was 67.2%, in which 24.5% (n = 25) were G1 heterozygous and 5.8% (n = 6) were G2 heterozygous and 37% of the patients had high-risk status with two alleles in homozygous (G1/G1 = 21 and G2/G2 = 3) or compound heterozygote (G1/G2 = 14) form.
format Online
Article
Text
id pubmed-6935820
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-69358202020-01-10 Prevalence of APOL1 Risk Variants in Afro-Descendant Patients with Chronic Kidney Disease in a Latin American Country Duran, Carlos E. Ramírez, Alejandro Posada, Juan G. Schweineberg, Johanna Mesa, Liliana Pachajoa, Harry Estacio, Mayra Manzi, Eliana Aros, Vanessa Díaz, Lorena Garcia, Victor H. Int J Nephrol Research Article INTRODUCTION: In Colombia, the genetic background of the populations was shaped by different levels of admixture between Natives, European, and Africans. Approximately 35.363 patients have diagnosed chronic kidney disease and according to population studies, 10.4% of these patients are Afro-descendant. We aim to assess the frequency of APOL1 variants G1 and G2 in Afro-descendant patients with ESRD treated at la Fundacion Valle del Lili University Hospital in Cali, Colombia. METHODS: This is an observational cross-sectional study. Afro-descendant patients with ESRD in waitlist or recipients of kidney transplant were evaluated. Clinical data were collected from the electronic medical records. Genotyping was carried out by amplification of the exon 7 of the APOL1 gene. For the identification of risk genotypes, the bioinformatics tool BLAST was used. RESULTS: We enrolled 102 participants. The frequency of APOL1 risk variants was 67.2%, in which 24.5% (n = 25) were G1 heterozygous and 5.8% (n = 6) were G2 heterozygous and 37% of the patients had high-risk status with two alleles in homozygous (G1/G1 = 21 and G2/G2 = 3) or compound heterozygote (G1/G2 = 14) form. Hindawi 2019-12-18 /pmc/articles/PMC6935820/ /pubmed/31929905 http://dx.doi.org/10.1155/2019/7076326 Text en Copyright © 2019 Carlos E. Duran et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Duran, Carlos E.
Ramírez, Alejandro
Posada, Juan G.
Schweineberg, Johanna
Mesa, Liliana
Pachajoa, Harry
Estacio, Mayra
Manzi, Eliana
Aros, Vanessa
Díaz, Lorena
Garcia, Victor H.
Prevalence of APOL1 Risk Variants in Afro-Descendant Patients with Chronic Kidney Disease in a Latin American Country
title Prevalence of APOL1 Risk Variants in Afro-Descendant Patients with Chronic Kidney Disease in a Latin American Country
title_full Prevalence of APOL1 Risk Variants in Afro-Descendant Patients with Chronic Kidney Disease in a Latin American Country
title_fullStr Prevalence of APOL1 Risk Variants in Afro-Descendant Patients with Chronic Kidney Disease in a Latin American Country
title_full_unstemmed Prevalence of APOL1 Risk Variants in Afro-Descendant Patients with Chronic Kidney Disease in a Latin American Country
title_short Prevalence of APOL1 Risk Variants in Afro-Descendant Patients with Chronic Kidney Disease in a Latin American Country
title_sort prevalence of apol1 risk variants in afro-descendant patients with chronic kidney disease in a latin american country
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6935820/
https://www.ncbi.nlm.nih.gov/pubmed/31929905
http://dx.doi.org/10.1155/2019/7076326
work_keys_str_mv AT durancarlose prevalenceofapol1riskvariantsinafrodescendantpatientswithchronickidneydiseaseinalatinamericancountry
AT ramirezalejandro prevalenceofapol1riskvariantsinafrodescendantpatientswithchronickidneydiseaseinalatinamericancountry
AT posadajuang prevalenceofapol1riskvariantsinafrodescendantpatientswithchronickidneydiseaseinalatinamericancountry
AT schweinebergjohanna prevalenceofapol1riskvariantsinafrodescendantpatientswithchronickidneydiseaseinalatinamericancountry
AT mesaliliana prevalenceofapol1riskvariantsinafrodescendantpatientswithchronickidneydiseaseinalatinamericancountry
AT pachajoaharry prevalenceofapol1riskvariantsinafrodescendantpatientswithchronickidneydiseaseinalatinamericancountry
AT estaciomayra prevalenceofapol1riskvariantsinafrodescendantpatientswithchronickidneydiseaseinalatinamericancountry
AT manzieliana prevalenceofapol1riskvariantsinafrodescendantpatientswithchronickidneydiseaseinalatinamericancountry
AT arosvanessa prevalenceofapol1riskvariantsinafrodescendantpatientswithchronickidneydiseaseinalatinamericancountry
AT diazlorena prevalenceofapol1riskvariantsinafrodescendantpatientswithchronickidneydiseaseinalatinamericancountry
AT garciavictorh prevalenceofapol1riskvariantsinafrodescendantpatientswithchronickidneydiseaseinalatinamericancountry